‘Cutting the cable’ between CD8+ T and T regulatory cells enhances checkpoint immunotherapy
Checkpoint immunotherapy utilising PD-1 blockade has become the standard of care for metastatic melanoma. While…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
Episode 11: On Advocacy and Revolutions: In Conversation with Matthew Zachary
Join Medical Oncologist Professor Bogda Koczwara AM and advocate Matthew Zachary, cancer survivor, founder of Stupid Cancer and the creative force behind the documentary Cancer Mavericks.
ASCO 2024: Novel CAR T cell therapy obe-cel yields strong remission rates in adults with relapsed or refractory B-ALL
The novel anti-CD19 autologous chimeric antigen receptor (CAR) T cell therapy obecabtagene autoleucel (obe-cel) achieved durable remissions…
ASCO 2024: Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal cancer
For patients with locally advanced oesophageal adenocarcinoma that can be treated with surgery, chemotherapy treatment…
Prenatal testing offers a window for finding a mother’s cancer risk
Harmful variants in the BRCA1 gene greatly increase a person’s lifetime risk of developing breast, ovarian and pancreatic…
Multicancer early detection tests for cancer diagnosis
Recent advancements in cancer research have led to the development of multicancer early detection (MCED)…
Inherited genes play a larger role in melanoma risk than previously believed
When it comes to skin cancer, most people think of warnings about sunburn and tanning…
One in four Thai concerned about colorectal cancer screening cost
According to research led by Prof. Varut Lohsiriwat, Professor of Surgery, Division of General Surgery (Section of…
Molecular profiling improves diagnosis and survival for children with high risk cancers
Cancer is the leading cause of disease-related death in children in most developed countries, and…
ASCO 2024: Trastuzumab deruxtecan significantly improves progression-free survival In breast cancer patients previously treated with endocrine therapy
Trastuzumab deruxtecan delays cancer growth for people with hormone receptor-positive (HR+), human epidermal growth factor…